1. Lobo M, Cerqueira C, Rodrigues AG, Lisboa C. Recurrent vulvovaginal candidosis and its underlying mechanisms: a systematic review. J Fungi. 2025;11(5):357. doi:10.3390/jof11050357.

2. Srb N, Talapko J, Meštrovic T, Fureš R, Stupnišek M, Srb AM, et al. A comprehensive overview of Candida albicans as the leading pathogen in vulvovaginal candidiasis. J Fungi. 2025;11(9):632. doi:10.3390/jof11090632.

3. Nobile CJ, Johnson AD. Candida albicans Biofilms and Human Disease. Annu Rev Microbiol. 2015;69:71-92. doi: 10.1146/annurevmicro-091014-104330.

4. Fan F, Liu Y, Liu Y, Lv R, Sun W, Ding W, et al. Candida albicans biofilms: antifungal resistance, immune evasion, and emerging therapeutic strategies. Int J Antimicrob Agents. 2022;60(5‑6):106673.

5. d’Enfert C, Kaune AK, Alaban LR, Chakraborty S, Cole N, Delavy M, et al. The impact of the fungus-host-microbiota interplay upon Candida albicans infections: current knowledge and new perspectives. FEMS Microbiol Rev. 2020;45(1):fuaa060.

6. Barantsevich N, Barantsevich E. Diagnosis and treatment of invasive candidiasis. Antibiotics. 2022;11(6):718.

7. Lass-Flörl C, Kanj SS, Govender NP, Thompson GR, OstroskyZeichner L, Govrins MA. Invasive candidiasis. Nat Rev Dis Primers. 2024;10(1):20.

8. Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187.

9. Ge G, Yang Z, Li D, Zhang N, Chen B, Shi D. Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis. Front Immunol. 2022 Jul 28;13:959740. doi: 10.3389/ fimmu.2022.959740.

10. Tian JY, Yang YG, Chen S, Teng Y, Li XZ. Genetic diversity and molecular epidemiology of Candida albicans from vulvovaginal candidiasis patients. Infect Genet Evol. 2021 Aug;92:104893. doi: 10.1016/j.meegid.2021.104893.

11. Li X, Chen S, Lyu X, Tian J. Virulence is one of the mechanisms of vulvovaginal candidiasis recurrence, rather than drug resistance. Med Mycol. 2022 Nov 18;60(11):myac087. doi: 10.1093/mmy/myac087.

12. Consuegra-Asprilla JM, Chaverra-Osorio M, Torres B, CabreraChingal Y, Mancera-Mieles A, Rodríguez-Echeverri C, et al. Landscape of in situ cytokine expression, soluble C-type lectin receptors, and vitamin D in patients with recurrent vulvovaginal candidiasis. Med Mycol. 2024;62(7):myae091.

13. Donders G, Bellen G, Byttebier G, Verguts L, Hinoul P, Walckiers R, et al. Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol. 2008;199(6):613.e1-613.e9.

14. Ghazanfari M, Falahati M, Fattahi A, Bazrafshan F, Nami S, Hosseinzadeh M, et al. Is mannose-binding lectin serum concentration a reliable predictor for recurrent vulvovaginal candidiasis? Mycoses. 2019;62(2):106-11.

15. Consuegra-Asprilla JM, Rodríguez-Echeverri C, Posada DH, Gómez BL, González Á. Patients with recurrent vulvovaginal candidiasis exhibit a decrease in both the fungicidal activity of neutrophils and the proliferation of peripheral blood mononuclear cells. Mycoses. 2024;67(4):e13720.

16. He X, Tang Q, Zhan F, Mao Y, Ye F, Weng Z, et al. Inflammatory invasion on human vaginal mucosa correlated with combined drug treatment and recurrence in recurrent vulvovaginal candidiasis. J Obstet Gynaecol Res. 2023;49(5):1443-51.

17. Hammad NM, El Badawy NE, Nasr AM, Ghramh HA, Al Kady LM. Mannose-Binding Lectin Gene Polymorphism and Its Association with Susceptibility to Recurrent Vulvovaginal Candidiasis. Biomed Res Int. 2018 Apr 4;2018:7648152. doi: 10.1155/2018/7648152.

18. Isakhani S, Naeimi S, Naeimi B, Ahmadi B. Genetic variation and upregulation of IL-12 enhance susceptibility to recurrent vulvovaginal candidiasis. Gene Rep. 2022;26:101463.

19. Jaeger M, Carvalho A, Cunha C, Plantinga TS, van de Veerdonk F, Puccetti M, et al. Association of a variable number tandem repeat in the NLRP3 gene in women with susceptibility to RVVC. Eur J Clin Microbiol Infect Dis. 2016;35(5):797-801.

20. Rosentul DC, Delsing CE, Jaeger M, Plantinga TS, Oosting M, Costantini I, et al. Gene polymorphisms in pattern recognition receptors and susceptibility to idiopathic recurrent vulvovaginal candidiasis. Front Microbiol. 2014;5:483.

21. Usluogullari B, Gumus I, Gunduz E, Kaygusuz I, Simavli S, Acar M, et al. The role of human Dectin-1 Y238X gene polymorphism in recurrent vulvovaginal candidiasis infections. Mol Biol Rep. 2014;41(10):6763-8.

22. Omosa-Manyonyi GS, Ponce IR, Rosati D, Bruno M, Kamau NW, Obimbo MM, et al. Genetic susceptibility to recurrent vulvovaginal candidiasis in an African population from Nairobi, Kenya. Sci Rep. 2025;15(1):12149. doi:10.1038/s41598-025-95772-7.

23. Mondragón Rosas E, González Flores JE, Zamudio Carías AD, García Martínez N, Díaz Salcedo EX, Navarro López PE, et al. Pathogenesis and Clinical Management of Vulvovaginal Candidiasis in Mexican Diabetic Patients: A Literature Review. Cureus. 2025 Jun 14;17(6):e86012. doi: 10.7759/cureus.86012.